- Home
- YQ vs MURA Comparison
YQ vs MURA Comparison
Compare YQ & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- MURA
- Stock Information
- Founded
- YQ 2012
- MURA 2013
- Country
- YQ China
- MURA Ireland
- Employees
- YQ N/A
- MURA N/A
- Industry
- YQ Other Consumer Services
- MURA
- Sector
- YQ Real Estate
- MURA
- Exchange
- YQ Nasdaq
- MURA Nasdaq
- Market Cap
- YQ 15.2M
- MURA 17.7M
- IPO Year
- YQ 2020
- MURA N/A
- Fundamental
- Price
- YQ $1.89
- MURA $2.56
- Analyst Decision
- YQ
- MURA Strong Buy
- Analyst Count
- YQ 0
- MURA 4
- Target Price
- YQ N/A
- MURA $13.00
- AVG Volume (30 Days)
- YQ 33.0K
- MURA 1.1M
- Earning Date
- YQ 06-04-2025
- MURA 05-20-2025
- Dividend Yield
- YQ N/A
- MURA N/A
- EPS Growth
- YQ N/A
- MURA N/A
- EPS
- YQ N/A
- MURA N/A
- Revenue
- YQ $25,922,648.00
- MURA N/A
- Revenue This Year
- YQ N/A
- MURA $34.35
- Revenue Next Year
- YQ N/A
- MURA N/A
- P/E Ratio
- YQ N/A
- MURA N/A
- Revenue Growth
- YQ 10.68
- MURA N/A
- 52 Week Low
- YQ $1.26
- MURA $0.95
- 52 Week High
- YQ $3.19
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- YQ 49.62
- MURA 53.24
- Support Level
- YQ $1.99
- MURA $2.48
- Resistance Level
- YQ $2.50
- MURA $2.72
- Average True Range (ATR)
- YQ 0.33
- MURA 0.10
- MACD
- YQ -0.00
- MURA 0.02
- Stochastic Oscillator
- YQ 25.23
- MURA 33.88
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.